On October 8, 2020, Mississippi Governor Tate Reeves signed into law a new bill allowing people to obtain cannabis-derived medications approved by the Food and Drug Administration.
Under the bill, federally approved cannabis medications would be removed from Schedule V of Mississippi’s drug code. The FDA has so far only approved one such drug, Epidiolex, which is used in the treatment of rare seizure disorders.
The bill comes as Mississippi also contemplates larger cannabis reforms. On November 3rd, citizens will be able to vote on Initiative 65, which would create a Mississippi medical cannabis program to provide citizens suffering from one of 22 listed medical conditions, including cancer and post-traumatic stress disorder, access to medical cannabis.
With a practical approach, Chad provides compliance guidance and litigation defense on matters related to cannabis, advertising and marketing, teleservices, and other consumer protection issues.